Company Overview and News

A Look into Roche Holding’s Performance in Q1 2018

2018-05-21 marketrealist
In the first quarter, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in the first quarter of 2017, which reflected ~5.0% growth on a YoY (year-over-year) basis.

Roche Tecentriq Combo Achieves Longer Overall Survival Rate

2018-05-17 zacks
Roche Holding AG (RHHBY - Free Report) announced encouraging interim data from a phase III study – IMpower150 – evaluating Tecentriq combination regimen for the first-line treatment of metastatic non-squamous non-small cell lung cancer ("NSCLC"). Data showed that its immuno-oncology drug, Tecentriq, in combination with its another blockbuster cancer drug Avastin plus carboplatin and paclitaxel, significantly improved median overall survival (“OS”) rate by 4.

Reducing Use of Roche Drug for Breast Cancer Didn’t Hurt Efficacy, Study Says - WSJ

2018-05-17 wsj
Treating breast-cancer patients with an expensive Roche Holding AG drug for six months instead of 12 reduced the medication’s heart-related side effects and its costs without sacrificing its effectiveness in preventing relapses, a new study found.

Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer

2018-05-17 zacks
Exelixis, Inc.’s (EXEL - Free Report) European partner Ipsen announced that the European Commission (EC) has granted approval to Cabometyx (cabozantinib) for an expanded indication. The EC approved Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (RCC) — a kind of kidney cancer in the European Union.

Study Finds More Isn't Better for Widely Used Breast Cancer Drug - Bloomberg

2018-05-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Is WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) a Hot ETF Right Now?

2018-05-16 zacks
Making its debut on 05/07/2014, smart beta exchange traded fund WisdomTree International Hedged Quality Dividend Growth Fund (IHDG - Free Report) provides investors broad exposure to the Broad Developed World ETFs category of the U.S. equity market.

Roche's Actemra Gets FDA Nod for Subcutaneous Formulation

2018-05-15 zacks
Roche Holding AG’s (RHHBY - Free Report) subsidiary Genentech announced that the FDA has approvedan alternative delivery option for itsrheumatoid arthritis drug Actemra. Asubcutaneous (SC) formulation of Actemra (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) for patients two years or older has been approved by the FDA.

Exelixis (EXEL) Q1 Earnings & Sales Top on Cabometyx Strength

2018-05-03 zacks
Exelixis, Inc. (EXEL - Free Report) delivered a stellar first-quarter 2018, wherein both earnings and revenues beat estimates on strong performance of Cabometyx.

Is a Beat in the Cards for Exelixis (EXEL) in Q1 Earnings?

2018-04-30 zacks
Exelixis, Inc. (EXEL - Free Report) is scheduled to report first-quarter 2018 results on May 2, after the market closes.

Roche (RHHBY) Q1 Earnings: Ocrevus, Perjeta Drive Sales Beat

2018-04-27 zacks
Roche Holding AG (RHHBY - Free Report) posted strong sales number for the first quarter of 2018 propelled by demand for new drugs amid biosimilar competition for legacy drugs.

Seattle Genetics (SGEN) Q1 Earnings Lag Estimates, Sales Top

2018-04-27 zacks
Seattle Genetics, Inc. (SGEN - Free Report) reported a loss of 61 cents per share for the first quarter of 2018, wider than the Zacks Consensus Estimate of 40 cents and the year-ago quarter loss of 42 cents.

Roche Holding's (RHHBY) CEO Severin Schwan on Q1 2018 Results - Earnings Call Transcript

2018-04-27 seekingalpha
Roche Holding Ltd ADR (OTCQX:RHHBY) Q1 2018 Earnings Conference Call April 26, 2018 8:00 AM ET

What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?

2018-04-26 zacks
Immune Design Corp. (IMDZ - Free Report) isscheduled to report first-quarter 2018 results after the market closes on May 2.

GSK Tries to Fix Pharma on a Budget - Bloomberg

2018-04-25 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

2018-04-23 zacks
Roche Holding AG (RHHBY - Free Report) announced encouraging data on multiple sclerosis (“MS”) drug Ocrevus at the 70th American Academy of Neurology (“AAN”) Annual Meeting, held from Apr 21-27 in Los Angeles, CA. The data revealed the efficacy of Ocrevus in relapsing multiple sclerosis (“RMS”) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (“MRI”), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...